ValuEngine upgraded shares of BioNano Genomics (NASDAQ:BNGO) from a hold rating to a buy rating in a research note published on Wednesday morning.
BNGO has been the topic of several other reports. Maxim Group assumed coverage on shares of BioNano Genomics in a report on Tuesday, September 25th. They issued a buy rating on the stock. Roth Capital assumed coverage on shares of BioNano Genomics in a report on Wednesday, September 26th. They issued a buy rating and a $12.00 price objective on the stock.
Shares of BNGO stock traded down $0.10 during trading hours on Wednesday, hitting $6.85. The company’s stock had a trading volume of 1,411 shares, compared to its average volume of 4,770. BioNano Genomics has a 12-month low of $5.51 and a 12-month high of $10.00.
BioNano Genomics Company Profile
BioNano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Read More: Should You Consider an Index Fund?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.